Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
22 participants
INTERVENTIONAL
2004-11-30
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
NCT01563107
Peripheral Dopamine in Postural Tachycardia Syndrome
NCT00685919
Dietary Salt in Postural Tachycardia Syndrome
NCT01547117
Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening
NCT01783288
Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration
NCT01064739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
10 mEq/day dietary sodium
dietary sodium
10 mEq/day
B
150 mEq/day dietary sodium
dietary sodium
150 mEq/day dietary sodium
C
300 mEq/day dietary sodium
dietary sodium
300 mEq/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dietary sodium
10 mEq/day
dietary sodium
300 mEq/day
dietary sodium
150 mEq/day dietary sodium
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* An increase in heart rate of \> 30 beats per minute upon standing, and
* Withdrawal of all medications for at least 3 days, and
* No associated medical illness, and
* Age 18 - 60 years old.
Exclusion Criteria
* Routinely taking medications affecting the autonomic nervous system
* Any chronic illness (cardiac, pulmonary, endocrine, gastrointestinal, rheumatologic) other than POTS
* Anemia (Hct \< 30)
* Women of childbearing age who are pregnant or nursing
* Unable to give informed consent
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanderbilt University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emily M. Garland
Research Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emily M Garland, PhD
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanderbilt University
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HL071784
Identifier Type: -
Identifier Source: secondary_id
040769
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.